Compass Pathways CSE: SHRM
Shares issued: 38,356,668
Share price: 0.33 cents upon listing
Champignon Brands is focused on producing and researching organic mushrooms for various biochemistry tests, but mainly for psilocybin. The company is selling mushroom derived teas online that claim to increase the immune system, elevate one’s mental state, decrease stress, enhance cognitive function, mood, memory,and energy, and cleanse and detoxify one’s body (specifically of what, it doesn’t say).
They also own drip coffee brick and mortar stores that will sell Champignon Brands. They have a cold-brew coffee, with mushroom extract blends. It doesn’t mention if psilocybin will be included in these products, but we expect that’s the direction of this product moving forward.
Champignon seems to be focused on testing for post traumatic stress disorder (PTSD) treatments, although the company mentions mostly tests completed by other companies or organizations. The company mentions a lot about the future of the industry, but not a lot of information about their strategy to take advantage of that. Certainly, in the coming year, Champignon will try to grow, primarily through acquisitions or testing psychedelics from plants and mushrooms, for both hallucinogenic and non-hallucinogenic medicines. Their pitch deck mentions microdosing, LSD, MDMA, and of course Psilocybin. It appears as though they want to be positioned if/when magic mushrooms become legalized.
Overall, the company is still a bit of a mystery, but we’re told they have excellent financial backers, who certainly will have a plan for the upcoming year. As of now, they seem to be one of the only early-to-the party names trading. With a tight share structure, Champignon should benefit greatly from the wave of investment that looks like it will flood into the psychedelic drug space.